Design of a bioactive cell-penetrating peptide: When a transduction domain does more than transduce

Journal of Peptide Science

Volumn 15, Issue 10, 2009, Pages 668-674

  Ward, Brian ^a   Seal, Brandon L ^a   Brophy, Colleen M ^b   Panitch, Alyssa ^a  

^a PURDUE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell penetrating peptide; Inhibitor specificity; Mitogen activated protein kinase activated protein kinase 2; Peptide therapeutics

Indexed keywords

CELL PENETRATING PEPTIDE; LYSYLALANYLPHENYLALANYLALANYLLYSYLLEUCYLALANYLALANYLARGINYLLEUCYLTRYSOSYLARGINYLLYSYLALANYLLEUCYLALANYLARGINYLGLUTAMYLLEUCYLGLYCYLVALYLALANYLALANINE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2 INHIBITOR; PHENYLALANYLALANYLLYSYLLEUCYLALANYLALANYLARGINYLLEUCYLTYROSYLARGINYLLYSYLALANYLLEUCYLALANYLARGINYLGLUTAMYLLEUCYLGLYCYLVALYLALANYLALANINE; TRYPTOPHANYLLEUCYLARGINYLARGINYLISOLEUCYLLYSYLALANYLTRYPTOPHANYLLEUCYLARGINYLARGINYLISOLEUCYLLYSYLALANYLLEUCYLASPARAGINYLARGINYLGLUTAMYLLEUCYLGLYCYLVALYLALANYLALANINE; TYROSYLALANYLARGINYLALANYLALANYLALANYLARGINYLGLUTAMYLALANYLARGINYLALANYLLYSYLALANYLLEUCYLALANYLARGINYLGLUTAMYLLEUCYLGLYCYLVALYLALANYLALANINE; TYROSYLALANYLARGINYLALANYLALANYLALANYLARGINYLGLUTAMYLALANYLARGINYLALANYLLYSYLALANYLLEUCYLASPARAGYLARGINYLGLUTAMYLLEUCYLGLYCYLVALYLALANYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IC 50; MESOTHELIUM CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CELL SURVIVAL; CELLS, CULTURED; DRUG DESIGN; EPITHELIAL CELLS; HSP20 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 70449686720     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1168     Document Type: Article

References (66)

1. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193. (Pubitemid 19020071)
2. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55: 1179-1188. (Pubitemid 19020070)
3. Saalik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, Langel U, Pooga M. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug. Chem. 2004; 15: 1246-1253. (Pubitemid 39552013)
4. Tkachenko AG, Xie H, Liu Y, Coleman D, Ryan J, Glomm WR, Shipton MK, Franzen S, Feldheim DL. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 2004; 15: 482-490. (Pubitemid 38657853)
5. Leifert JA, Harkins S, Whitton JL. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 2002; 9: 1422-1428. (Pubitemid 35345570)
6. Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry 2002; 41: 12652-12661. (Pubitemid 35192494)
7. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 2001; 61: 474-477. (Pubitemid 32128600)
8. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. Thedesign, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 13003-13008.
9. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994; 269: 10444-10450. (Pubitemid 24198241)
10. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 1864-1868. (Pubitemid 21916327)
11. Joliot A, Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell Biol. 2004; 6: 189-196.
12. Gump JM, Dowdy SF. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 2007; 13: 443-448.
13. El-Andaloussi S, Holm T, Langel U. Cell-penetrating peptides: mechanisms and applications. Curr. Pharm. Des. 2005; 11: 3597-3611.
14. Gaestel M. MAPKAP kinases-MKs-two's company, three's a crowd. Nat. Rev. Mol. Cell Biol. 2006; 7: 120-130. (Pubitemid 43278295)
15. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell. Signal. 2000; 12: 1-13. (Pubitemid 30017963)
16. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004; 68: 320-344. (Pubitemid 38756868)
17. Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J. Biol. Chem. 2002; 277: 42596-42602. (Pubitemid 35285628)
18. Tilly BC, Gaestel M, Engel K, Edixhoven MJ, de Jonge HR. Hypo-osmotic cell swelling activates the p38 MAP kinase signalling cascade. FEBS Lett. 1996; 395: 133-136. (Pubitemid 26356170)
19. Engel K, Ahlers A, Brach MA, Herrmann F, Gaestel M. MAPKAP kinase 2 is activated by heat shock and TNF-alpha: in vivo phosphorylation of small heat shock protein results from stimulation of the MAP kinase cascade. J. Cell. Biochem. 1995; 57: 321-330.
20. Belka C, Ahlers A, Sott C, Gaestel M, Herrmann F, Brach MA. Interleukin (IL)-6 signaling leads to phosphorylation of the small heat shock protein (Hsp)27 through activation of the MAP kinase and MAPKAP kinase 2 pathway in monocytes and monocytic leukemia cells. Leukemia 1995; 9: 288-294.
21. Ahlers A, Engel K, Sott C, Gaestel M, Herrmann F, Brach MA. Interleukin-3 and granulocyte-macrophage colony-stimulating factor induce activation of the MAPKAP kinase 2 resulting in in vitro serine phosphorylation of the small heat shock protein (Hsp 27). Blood 1994; 83: 1791-1798. (Pubitemid 24107901)
22. Ahlers A, Belka C, Gaestel M, Lamping N, Sott C, Herrmann F, Brach MA. Interleukin-1-induced intracellular signaling pathways converge in the activation of mitogen-activated protein kinase and mitogen-activated protein kinase-activated protein kinase 2 and the subsequent phosphorylation of the 27-kilodalton heat shock protein in monocytic cells. Mol. Pharmacol. 1994; 46: 1077-1083.
23. Clifton AD, Young PR, Cohen P. A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress. FEBS Lett. 1996; 392: 209-214. (Pubitemid 26289115)
24. Kotlyarov A, Gaestel M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression?. Biochem. Soc. Trans. 2002; 30: 959-963.
25. Ronkina N, Kotlyarov A, Gaestel M. MK2 and MK3 - a pair of isoenzymes? Front. Biosci. 2008; 13: 5511-5521.
26. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1999; 1: 94-97. (Pubitemid 129501950)
27. Tietz AB, Malo A, Diebold J, Kotlyarov A, Herbst A, Kolligs FT, Brandt-Nedelev B, Halangk W, Gaestel M, Goke B, Schafer C. Gene deletion of MK2 inhibits TNF-alpha and IL-6 and protects against cerulein-induced pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290: G1298-G1306. (Pubitemid 43788313)
28. Gorska MM, Liang Q, Stafford SJ, Goplen N, Dharajiya N, Guo L, Sur S, Gaestel M, Alam R. MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J. Exp. Med. 2007; 204: 1637-1652. (Pubitemid 47048030)
29. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U. Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ. Res. 2007; 101: 1104-1112. (Pubitemid 350146436)
30. Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2006; 281: 23658-23667. (Pubitemid 44274141)
31. Thomas T, Hitti E, Kotlyarov A, Potschka H, Gaestel M. MAP-kinase-activated protein kinase 2 expression and activity is induced after neuronal depolarization. Eur. J. Neurosci. 2008; 28: 642-654.
32. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175-189.
33. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J. Immunol. 2006; 177: 1913-1917. (Pubitemid 44092531)
34. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, Tsichlis P, Cominelli F, Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 2002; 196: 1563-1574. (Pubitemid 36026468)
35. Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 2007; 14: 2214-2234. (Pubitemid 47570683)
36. Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Biochem. Biophys. Res. Commun. 2009; 382: 535-539.
37. Hayess K, Benndorf R. Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem. Pharmacol. 1997; 53: 1239-1247. (Pubitemid 27305623)
38. Lukas TJ, Mirzoeva S, Slomczynska U, Watterson DM. Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J. Med. Chem. 1999; 42: 910-919. (Pubitemid 29136180)
39. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 2000;10:290-295.
40. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-256. (Pubitemid 32846431)
41. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 2001; 61: 474-477. (Pubitemid 32128600)
42. Wadia JS, Dowdy SF. Protein transduction technology. Curr. Opin. Biotechnol. 2002; 13: 52-56.
43. Seal BL, Panitch A. Physical polymer matrices based on affinity interactions between peptides and polysaccharides. Biomacromolecules 2003; 4: 1572-1582. (Pubitemid 37455568)
44. Tyler-Cross R, Sobel M, McAdory LE, Harris RB. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. Arch. Biochem. Biophys. 1996; 334: 206-213. (Pubitemid 26347302)
45. Bodanszky M. Peptide Chemistry : A Practical Textbook. Springer-Verlag: Berlin; New York; 1988.
46. Zu YL, Wu F, Gilchrist A, Ai Y, Labadia ME, Huang CK. The primary structure of a human MAP kinase activated protein kinase 2. Biochem. Biophys. Res. Commun. 1994; 200: 1118-1124. (Pubitemid 24146078)
47. Stokoe D, Caudwell B, Cohen PT, Cohen P. The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2. Biochem. J. 1993; 296(Pt 3): 843-849. (Pubitemid 24008205)
48. Frodin M, Antal TL, Dummler BA, Jensen CJ, Deak M, Gammeltoft S, Biondi RM. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. Embo J. 2002; 21: 5396-5407. (Pubitemid 35231019)
49. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J. Cell. Sci. 1997; 110(Pt 3): 357-368. (Pubitemid 27095655)
50. McLaughlin MM, Kumar S, McDonnell PC, Van Horn S, Lee JC, Livi GP, Young PR. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J. Biol. Chem. 1996; 271: 8488-8492. (Pubitemid 26108688)
51. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78: 1027-1037. (Pubitemid 24292330)
52. Haydon CE, Watt PW, Morrice N, Knebel A, Gaestel M, Cohen P. Identification of a phosphorylation site on skeletal muscle myosin light chain kinase that becomes phosphorylated during muscle contraction. Arch. Biochem. Biophys. 2002; 397: 224-231. (Pubitemid 34852284)
53. Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, Tegge WJ. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 14772-14777. (Pubitemid 32016649)
54. Meng W, Swenson LL, Fitzgibbon MJ, Hayakawa K, Ter Haar E, Behrens AE, Fulghum JR, Lippke JA. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J. Biol. Chem. 2002; 277: 37401-37405.
55. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 2005; 17: 37-48. (Pubitemid 40075363)
56. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008; 26: 127-132.
57. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000; 351: 95-105. (Pubitemid 30781561)
58. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003; 371: 199-204. (Pubitemid 36458094)
59. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. 3rd A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005; 23: 329-336. (Pubitemid 41094421)
60. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 1998; 8: 84-87. (Pubitemid 28056816)
61. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 2002; 45: 3612-3618. (Pubitemid 34856101)
62. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 2000; 56: 318-325. (Pubitemid 30800261)
63. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001; 276: 5836-5840. (Pubitemid 33647928)
64. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol.chem. 1995;270: 14255-14258.
65. Lehner MD, Schwoebel F, Kotlyarov A, Leist M, Gaestel M, Hartung T. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J. Immunol. 2002; 168: 4667-4673. (Pubitemid 34441374)
66. Prochiantz A. For protein transduction, chemistry can win over biology. Nat. Methods 2007; 4: 119-120. (Pubitemid 46454677)